About Vektor Pharma
Innovative solutions for efficient drug delivery
Delivering drug formulations through transdermal or sublingual methods are effective and non-invasive ways to treat common neurological conditions.
Working Together
The Vektor and XPhyto Partnership
Design, Testing, and Manufacturing
Vektor Pharma is a leader in the design, testing and manufacture of thin film drug formulations to innovate the delivery methods of treatment, including transdermal patches and oral strips. There are promising opportunities being explored to utilize these innovative drug delivery methods with the application of cannabis. Vektor is preparing for growth by adding scalable, in-house manufacturing capability for the commercialization of these innovative solutions.
Exclusive Narcotic Usage and Agreement
Vektor holds a number of valid narcotics licenses, including an import permits for drug dosage forms and cannabis; manufacturing permits for clinical samples and final drug product releases; an analytical permit for chemical and physical testing; and permits to handle narcotic drugs and animal tissues. These permits accelerate XPhyto’s advancements in medicinal cannabis.
“Our vision is efficient and accessible transdermal delivery of medicine for the most common neurological diseases with accessibility for those who need it.”
– Hugh Rogers, CEO
Our Products in Development with Vektor Pharma
Rotigotine Transdermal Patch
Clinical studies are planned in 2021 to advance our research into the potential treatment of Parkinson's disease.
CBD Oral/Sublingual Strip
Clinical studies are planned in 2021 to advance our research into the potential impact for treatment-resistant Epilepsy.
THC Oral/Sublingual Strip
Clinical studies are planned in 2021 to advance our research into the potential impact for anorexia and nausea.
Be in the know. Get our press releases and latest news first.
Hear about our latest research, products, exclusive partnerships & more.